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Abstract. The aim of the study was to develop a population pharmacokinetic (PK) model for clearance of 2-oxo-clopidogrel 
in patients with acute coronary syndrome (ACS). Population pharmacokinetic analysis was performed by using 72 plasma 
concentrations from the same number of patients (mean age of 60.82±10.76 years; total body weight (TBW) of 73.63±9.67 
kg) with ACS using non-linear mixed-effect modeling (NONMEM). Validation of the final PPK model was carried out 
through the bootstrap analysis with 200 runs and it was used to estimate the predictive performance of the pharmacokinetic 
model. The typical mean value for 2-oxo-clopidogrel clearance (CL), estimated by the base model (without covariates), in 
our population was 39.2 l h−1.The value of aspartate transaminase and co-medication with digoxin were determinants of a 
derived population model. The final regression model for the clearance of 2-oxo-clopidogrel was the following: CL (lh
-1
) = 
1.7 + 1.31*AST + 115*DIGOXIN. The derived PK model describes the clearance of 2-oxo-clopidogrel in patients with 
ACS, showing that the value of aspartate transaminase and co-medication with digoxin are the most important covariate. 
This finding will provide the basis for future PK studies. 
Key words: 2-oxo-clopidogrel, acute coronary syndrome, population pharmacokinetics, clearance, Nonlinear mixed 
effects model (NONMEM). 
Introduction

 
Clopidogrel, a second generation thienopyridine, is P2Y12 
subtype of adenosine diphosphate (ADP) receptor antago-
nist. To date, a large number of conducted studies have 
shown clinical benefit of treatment with clopidogrel in 
addition to aspirin as dual antiplatelet therapy for acute 
coronary syndrome (ACS) and/or undergoing percutaneous 
coronary intervention (PCI) [13]. It is still cornerstone 
antiplatelet therapy for coronary heart disease despite some 
advantages of new P2Y12 receptor antagonists such as 
prasugrel and ticagrelor [4, 5]. The higher treatment cost of 
novel antiplatelet drugs, as well as its higher risk of major 
bleeding, maintained clopidogrel as first –line therapy 
option and extensively prescribed drug worldwide.  
Clopidogrel is a prodrug, and its biotransformation by a 
2-step, cytohrome P450 - dependent process, is requested for 
conversion to its active metabolite. Introduction of one 
oxygen atom into clopidogrel, and its conversion to 2-oxo-
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clopidogrel is the first step of its hepatic metabolism with 
contribution of CYP1A2, CYP2B6, and CYP2C19 by 
35.8, 19.4 and 44%, respectively [6]. In the next oxidation 
process, 2-oxo-clopidogrel is converted into the pharma-
cologically active metabolite R-130964 by CYP2B6 
(32.9%), CYP2C9 (6.76%), CYP2C19 (20.6%), and 
CYP3A4 (39.8%) enzymes [7]. The genes encoding 
CYP3A4/5 and CYP2C19 are polymorphic and accounta-
ble in variability of clopidogrel pharmacokinetics. Based 
on the available information regarding a correlation be-
tween both pharmacokinetic parameters of clopidogrel and 
H4, active metabolite of clopidogrel, as well as the Cmax 
of the H4 isomer and platelet aggregation, the intestinal 
absorption of clopidogrel may be considered as rate-limit-
ing process [6, 8]. Additionally, the latter observations 
allowed the prediction of pharmacodynamics response to 
clopidogrel using pharmacokinetic data on clopidogrel or 
2-oxo-cxopidogrel. Furthermore, previous publications 
have suggested both active metabolite’s instability and 
existance in the plasm for a short period [6, 9]. In accord-
ance with the previously mentioned, in this study we eval-
uated the clinical and demographic factors that influence 2-
oxo-clopidogrel clearance, supposing this is relevant for 
vicagrel, novel analog of clopidogrel and its further devel-
opment in phase II/III studies [10]. 
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The focus of our study was the evaluation PK varia-
bility of 2-oxo-clopidogrel in patients with acute coronary 
syndrome (ACS) using the population PK approach. 
Methods 
Patient Data 
The investigation was performed at the Clinic of Cardiol-
ogy, Clinical Center Niš, Serbia during three months (from 
February to May 2016) after obtaining permission of the 
Ethics Committee of the University of Nis, Faculty of 
Medicine. All patients were informed about the details 
related to the study protocol and were included after their 
written consent. The including criteria were: patients of 
both sexes older than 18 years, with diagnosis of acute 
coronary syndrome (ACS) with/without ST-elevation as 
confirmed by the cardiologists, using the electrocardiogram 
and the biochemical tests. The exclusion criteria for our 
study were: pregnant and lactating women, presence of 
mental disorders and patients’ refusal to participate in the 
study. 
Our study population consisted of 72 patients treated 
with clopidogrel in accordance with Institutional Re-
view Board/Human Subjects Research Committee re-
quirements. The dual antiplatelet therapy (acetylsali-
cylic acid and clopidogrel) was administered in all pa-
tients. Clopidogrel loading dose was 300mg or 600 mg 
and it varied depending on the revascularization proce-
dure (PCI or fibrinolytics) and patients’ status. After 
that, clopidogrel was administered once daily, at the 
maintenance dose of 75mg or 150mg. Besides that, all 
patients also received angiotensin-converting enzyme 
(ACE) inhibitors and other drugs presented in Table 1. 
This data and other clinical and demographic data of 
patients (ejection fraction (ER), their concomitant dis-
eases, total body weight (TBW), age of patients and 
sex), were obtained from medical records, while data of 
life habits were recorded in a conversation with patients.  
Blood sampling and laboratory analysis  
The study protocol included taking four blood samples 
from all patients: two for the routine laboratory tests 
immediately after the admission of patients to hospital, 
and two blood samples after three days of starting ther-
apy with clopidogrel for the patients’ genotyping and 
measuring of the drug concentrations, respectively. 
Oxoclopidogrel concentrations were measured from 
the serum samples at the steady–state concentrations 
using the ultrahigh-performance liquid chromatography 
with diode array detector-mass spectrometry analysis 
(UHPLC-DAD-MS). The UHPLC was carried out on a 
Dionex Ultimate 3000 UHPLC system equipped with a 
DAD-detector and also connected to LCQ Fleet Ion 
Trap Mass Spectrometer (Thermo Fisher Scientific, 
USA). The process of separations was performed on a 
Poroshell 120 EC-C18 column (4.6×50mm, 2.7μm; Ag-
ilent technology, USA) at room temperature (25
◦
C). The 
absorption was recorded on DAD-detector (with total 
spectral range between 200nm and 800nm), set at three 
detection wavelengths of 240, 220 and 300nm, simulta-
neously. Mass spectrometric analysis was performed 
using an LCQ 3D-ion trap mass spectrometer with elec-
trospray ionization (ESI) in positive ion mode. MS-
spectra were acquired by full range acquisition of m/z 
300–500. For fragmentation study (MS/MS), a data de-
pendent scan was performed by deploying the collision–
induced dissociation at 25eV. The range of the linearity 
for oxoclopidogrel was …with the lowest the limit of 
detection and quantification of serum concentration of 
oxoclopidogrel was 0.5ng/mL and 50.0 ng/mL respec-
tively. All the serum samples for this type of the analy-
sis were obtained in Cmax concentrations, two hours 
after oral administration of morning dose of clopidogrel.  
The patients’ genotyping analysis was included before 
isolating manually the genomic DNA from the whole 
blood leukocytes and the following small nuclear poly-
morphisms (SNPs) which was determined by using the 
PCR (polymerase chain reaction) method: ABCB1 
C34335T (rs1045642), CYP2C19*2 (rs4244285) and *17 
(rs12248560), as well as CYP2C9*2 (rs1799853). The 
commercial mix KAPA2G Readymix (KAPA2G Ready-
Mix FastHotStart; Kappa Biosystems, Boston, MA, USA), 
the reaction mixture with specific primers were used for 
SNPs detections. For detection of gene polymorphism of 
ABCB1 C3435T were used primers C (5'−GGTGTCA 
CAGGAAGAGATC−3'), (5'−CAGCCGGGTATAGTCA 
CAGGAAGATATT−3') and the reverse  (5'−GGCCAGA 
GAGGCTGCCACAT−3'), for the detection of gene 
polymorphism of CYP2C19*2 primers were used the 
forward (5'−AATTACAACCAGAGCTTGGC−3'), the 
reverse (5'−TATCACTTTCCATAAAAGCAAG−3'), for the 
recorded of gene polymorphism of CYP2C19*17 used the 
forward (5'−GCCCTTAGCACCAAATTCTC−3') and the 
reverse (5'−ATTTAACCCCCTAAAAAAACACG−3') and 
the end for the detection of CYP2C9*2 gene polymor-
phism was used the forward (5'−GTATTTTGGCCTGA 
AACCCATA−3') and the reverse (5'−GGCCTTGGTT 
TTTCTCAACTC−3'). The reaction condition consisted of 
the initiation at 95°C for 2 minutes followed by  different 
number of cycles. In the case of ABCB1 no restriction 
enzyme was used, since the primers were allele specific. 
SNPs determination was performed after vertical 
electrophoresis in 8% polyacrylamide gel (ABCB1 
C3435T and CYP2C19*2) or horizontal electrophoresis in 
2% agarose gel (CYP2C19*17 and CYP2C9*2). 
Pharmacokinetic analysis 
For population pharmacokinetics (PPK) analysis of oxo-
clopidogrel and the estimates of its pharmacokinetics pa-
rameters (PK) of the target population, we applied the 
NONMEM software (version 7.3.0.) (Icon Development 
Solutions, USA) with ADVAN 1 subroutine which well 
describes a one-compartment model without absorption 
[11]. This model has given the best estimate of the main 
PK parameters of oxoclopidogrel, the apparent oral clear-
ance (CL/F) and its inter-individual and residual (intra-
individual) variability. The choice of appropriate subrou-
tine was based on the literature data of clopidogrel and 
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oxoclopidogrel pharmacokinetics and testing of different 
PPK models (using the lowest value of the minimum of 
objective function (MOF) as the mean statistical criteria 
between the tested models). In this step, with the aim to 
form the base PPK model of investigated drug, we also 
analyzed  various models errors for the estimation of varia-
bility, using an exponential, additive, proportional and 
combined model errors. The parent drug, clopidogrel was 
administered orally in all patients and the influence of oral 
bioavailability (F) was not considered in the analysis. The 
base PPK model of oxoclopidogrel was built using the 
collected data of 72 patients with ADVAN1 subroutine 
from the software library (without tested covariate). 
Covariate of interest for the PPK analysis of oxoclo-
pidogrel were the following: total body weight, age, sex, 
total daily dose of clopidogrel, ejection fraction, cholesterol 
and triglyceride levels, red blood cells (RBC) count, creati-
nine clearance (calculated for each patient using the Cock-
croft-Gault equation), aspartate transaminase (AST) and 
alanine transaminase (ALT), ABCB1 and CYP2C9 geno-
types, CYP2C19 phenotype, concomitant disease as the 
presence of diabetes mellitus (DM)  type 2, life habits such 
as smoking status of patient and co-medication with other 
drugs: beta-blockers, diuretics, spironolactone, amlodipine, 
amiodarone, digoxin, pantoprazole, sulphonylureas and 
statins (atorvastatine, rosuvastatine and simvastatine). The 
influence of 25 covariates on the pharmacokinetic dispo-
sition of oxoclopidogrel, were analyzed through the uni-
variate regression models. This process consisted of adding 
only one of tested covariate in the base model (in a linear 
or nonlinear way), and then, its statistical significance was 
assessed on the reduction in the MOF value between this 
model and the base PPK model. The MOF is defined as -
2loglikelihood and, therefore, its required reduction was at 
least 6.63 (p<0.01, df=1). As the results of this complex 
process, we recorded all covariate with the significant in-
fluences on the PK parameters of oxoclopidogrel, and after 
that, were added in the full model, simultaneously. Further, 
the analysis was performed in the opposite manner, re-
moving each individual covariate from the full model and 
noting the differences in the MOF value. In this process of 
backward removal, the main statistical criteria was 
stronger, with increasing of the MOF values by ≥10.83 
(p<0.001, df=1) [12]. Thus, the final PPK model of oxo-
clopidogrel consisted of only those covariate which satis-
fied both approach selection processed (forward addition 
and backward removal), suggesting their particular influ-
ence on pharmacokinetics of the investigated drug. Integral 
part of this analysis was a graphic inspection of data fitting 
between predicted, population values of concentration 
versus obtained, measured concentrations of oxoclo-
pidogrel, which was obligatory conducted during all 
phases.  
Validation of the final PPK model was carried out 
through the bootstrap analysis with 200 runs. This type of 
the internal validation was recommended for a small num-
ber of samples per patient by the Guidance for Industry 
Population Pharmacokinetics, FDA, for the estimation of 
the stability and predictive performances of the final PPK 
model [13]. Values of PK parameters and its variability 
from the bootsrap analysis were compared with the values 
from NONMEM analysis and if similar, that indicated a 
good predictive performance of the derived PPK model. 
Results 
The study population consisted of 72 patients of both 
sexes (28 female and 44 male) in order to assess the 
mean population value of the clearance of oxoclo-
pidogrel, as the main metabolite of clopidogrel. The 
range of patients age was 37 to 85 years, including mid-
dle-age to elderly patients, with the average value of 
Table 1 Respondent’s characteristics (demographic, 
biochemical, genetic and clinical data) 
Characteristics of population Investigated set 
(mean values  
 SD*) 
Range of 
investigated 
set 
Number of patients 72  
Number of observations 72  
Gender (male/female) 44/28  
TBW (kg) 73.63 ± 9.67 55106 
Age (years) 60.82 ± 10.76 3785 
Clopidogrel daily dose 
(mg/day) 
84.38 ± 24.98 75150 
Oxoclopidogrel plasma 
concentration (mg/l) 
 0.29. ± 0.39 0.0008 
 1.7309 
ABCB1 genotype: 
- CC 
- CT 
- TT 
72 
- 19 
- 34 
- 19 
 
CYP2C19 phenotype: 
- PM 
- IM 
- EM 
- URM 
72 
- 4 
- 19 
- 25 
- 24 
 
CYP2C9 genotype: 
-CC 
-CT 
-TT 
72 
- 56 
- 15 
- 1 
 
Ejection fractions (%)  51.32 ± 12.27 2879 
Cholesterol levels (mmol/l)  5.52 ± 1.35 2.9510.87 
Triglyceride levels (mmol/l)  2.19 ± 3.85 0.1433 
RBC counts (10
12
/l)  4.66 ± 0.68 3. 76.12 
AST (U/l)  117.21 ± 169.81 10.2930 
ALT (U/l)  34.20 ± 26.57 1.27146.7 
Creatinine clearance (l h
-1
)     4.38 ± 1.47 1.287.23 
Diabetes mellitus  19  
Smokers 24  
Co-medications with: 
- Pantoprazole 
- Beta blockers 
- Diuretics 
- Spironolactone 
- Amlodipine 
- Amiodarone 
- Digoxin 
- Sulphonylureas 
- Statins: 
   - Atorvastatine 
   - Rosuvastatine 
   - Simvastatine 
 
- 58 
- 49 
- 21 
-14 
-12 
- 8 
- 8 
- 4 
- 69 
- 60 
- 2 
- 7 
 
*SD- standard deviation 
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body weight of 74kg. Clopidogrel tablets were routinely 
administered orally, once daily at the dose of 75mg 
(n=63, 87.5%) or 150mg (n=9, 12.5%). The presence of 
DM type 2 was showed as the most common concomi-
tant disease (n=19, 26.39%), while almost a third of the 
population were active smokers (n=24, 33.33%). In 
terms of co-medications with other drugs, three groups 
were administered most frequently: statins (95.83%) as 
the drugs that reduce cholesterol levels (atorvastatine 
(83.33%), rosuvastatine (2.78%) and simvastatine 
(9.72%)), the gastroprotective therapy with the proton 
pump inhibitors (PPIs) (pantoprasole (80.56%)) and 
beta blockers (BBs) (68.06%). The other co-adminis-
tered drugs were: diuretics (29.17%), spironolactone 
(19.44%), amlodipine (16.67%), amiodarone (11.11%), 
digoxin (11.11%) and sulfonylurea derivatives (5.56%).  
The average serum concentration of oxoclopidogrel was 
0.29±0.39 followed with a wide range from 0.0008 to 
1.730mg per liter in the population. Overall, demo-
graphic data, biochemical, genetic and clinical data of 
the respondents are presented in Table 1.  
The mean population value of oxoclopidogrel clear-
ance without examining the effects of different covariate 
was 39.2 liters per hour in the base model. This analysis 
was carried out using one compartmental model with no 
absorption from NONMEM software, since the active 
metabolite was the objective of our investigation. Further, 
the process of forward selection was conducted in order to 
assess the influence of each individual factor on pharma-
cokinetics disposition of the drug. The values of MOF, 
evaluated by univariate models which examined the effects 
of separate factors on oxoclopidogrel clearance, are shown 
Table 2 Values of MOF for the base model and univariate regression models of examined covariates with their statistical 
significance in the process of building of the full PPK model  
Clearance models 
 
Minimum of objective function p-value 
**
 
BASE  MODEL  
CL= θ1 *EXP(ETA(1)) 
 
1047.867 
 
UNIVARIATE REGRESSION MODELS 
CL= θ1*EXP(ETA(1)) + θ2 *AGE 
 
1030.711 
 
<0.01 
CL= θ1*EXP(ETA(1)) + θ3 * TBW 1046.725 >0.01 
CL= θ1*EXP(ETA(1))  θ4* SEX 1047.867 >0.01 
CL= θ1*EXP(ETA(1)) + θ5* DD 1047.108 >0.01 
CL= θ1*EXP(ETA(1))  θ6* ABCB1 1046.007 >0.01 
CL= θ1*EXP(ETA(1))  θ7* CYP2C19 genotype 1046.103 >0.01 
CL= θ1*EXP(ETA(1))  θ8* CYP2C9 genotype 1046.477 >0.01 
CL= θ1*EXP(ETA(1)) + θ9* EF 1047.001 >0.01 
CL= θ1*EXP(ETA(1))  θ10* CHOL 1031.930 <0.01 
CL= θ1*EXP(ETA(1))  θ11* TGL 1047.449 >0.01 
CL= θ1*EXP(ETA(1))  θ12* RBC  1047.867 >0.01 
CL= θ1*EXP(ETA(1))  θ13* AST   990.892 <0.01 
CL= θ1*EXP(ETA(1))  θ14* ALT 1047.866 >0.01 
CL= θ1*EXP(ETA(1))  θ15* CLcr 1047.138 >0.01 
CL= θ1*EXP(ETA(1))  θ16* DM 1047.867 >0.01 
CL= θ1*EXP(ETA(1))  θ17* TOB 1047.524 >0.01 
CL= θ1*EXP(ETA(1))  θ18* PANT 1047.424 >0.01 
CL= θ1*EXP(ETA(1))  θ19* BB 1047.867 >0.01 
CL= θ1*EXP(ETA(1))  θ20* DIU 1047.867 >0.01 
CL= θ1*EXP(ETA(1))  θ21* SPI 1047.860 >0.01 
CL= θ1*EXP(ETA(1))  θ22* AML 1047.867 >0.01 
CL= θ1*EXP(ETA(1))  θ23* AMI 1040.078 <0.01 
CL= θ1*EXP(ETA(1))  θ24* STAT 1047.867 >0.01 
CL= θ1*EXP(ETA(1))  θ25* DIG 1035.918 <0.01 
CL= θ1*EXP(ETA(1))  θ26* SUL 1047.867 >0.01 
FULL MODEL  
CL= θ1 *EXP(ETA(1)) + 0.0000000845 * AGE 
+0.000000717*CHOL1.31*AST0.00000101*AMI 115*DIG 
 
 
985.943 
 
CL clearance (l/h); θ1 typical value of CL; ETA (1) interindividual variability in CL; θ2 to θ26 slopes of the covariate effects; TBW patient´s 
body weight (kg); SEX takes the value 1 for male and 0 for female; DD daily dose of clopidogrel (mg/day); ABCB1 genotype (C=wild 
type, T=increased P-glycoprotein activity); CYP2C19 phenotype (PM=poor metabolizer, IM=intermediate metabolizer, EM=extensive 
metabolizer, URM=ultrarapid metabolizer); CYP2C9 genotype (C=wild type, T=decreased activity); EF ejection fractions; CHOL 
cholesterol; TGL triglyceride; RBC red blood cells; AST aspartate transaminase; ALT alanine transaminase; CLcr creatinine clearance (l 
h-1); DM presence of diabetes mellitus; TOB takes the value 1 for smokers and 0 for non-smokers; co-medication with PANT 
pantoprazole, BB beta blockers, DIU diuretics, SPI spironolactone, AML amlodipine, AMI amiodarone, STAT statine, DIG digoxin, SUL 
sulphonylureas takes the value 1 if the patient received co-medication and 0 otherwise.  
**p-value for the MOF difference between the base and tested models  
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in Table 2. Required statistical significance (for p<0.001) 
in this step was the minimal difference in the MOF values 
of 6.63 between the base and a single regression model.  
Thus, the full model consisted of the following co-
variates: age, cholesterol level, aspartate transaminase 
and co-medications with amiodarone and digoxin. Its 
effects on clearance of oxoclopidogrel had to be con-
firmed by the backward removal process with the strong 
statistical requirements (difference in MOF ≥10.83 for 
p<0.001). In the next table, marked as Table 3, we pre-
sented this process which resulted in the confirmation of 
two covariates with significant influence on the apparent 
clearance of oxoclopidogrel and its variability. These 
were the value of aspartate transaminase and co-medica-
tion with digoxin in the target population, described in the 
form of the equation as:  
CL (lh
-1
) = 1.7 + 1.31*AST + 115*DIGOXIN 
Table 3 The process of backward removal of covariate 
from a full PPK model of the clearance of 
oxoclopidogrel  
Covariates Difference in minimum 
objective function 
p-value 
**
 
Age 
Cholesterol 
AST 
Amiodarone 
Digoxin 
1.798 
1.557 
50.084 
0.969 
17.162 
>0.001 
>0.001 
<0.001 
>0.001 
<0.001 
**p-value for the MOF difference between the base and tested 
models  
During the PPK analysis, the value of MOF was re-
duced by 61.924 units from the base to the final model. 
Furthermore, both inter-individual and residual varia-
bility (expressed as coefficient of variation) were 
31.18% and 59.72% in the base model and were re-
duced to 16.01% and 41.51% in the final model, re-
spectively. Much better correlation between measured 
oxoclopidogrel concentrations versus its population, 
predicted concentrations (ng/ml) in the final model is 
shown in Figure 1. The estimates of the apparent clear-
ance of oxoclopidogrel, both investigated variability, 
and also the effects of aspartate transaminase and co-
medication with digoxin, are confirmed by the bootstrap 
analysis indicating a good precision and the stability of 
the final model (Table 4). 
Discussion 
In the present study we developed and used a population 
pharmacokinetic model for the clearance of 2-oxo-
clopidogrel in routinely treated Serbian patients with 
ACS. We observed that the typical mean value for 2-
oxo-clopidogrel clearance, estimated by the base model 
(without covariates) in our population was 39.2 l h
-1
. 
Also, we noted large interindividual and residual varia-
bilities in this phase. 
Another potential source of pharmacokinetics vari-
ance of 2-oxo-clopidogrel is metabolic activity of CYP 
enzyme, especially the activity of CYP2C19 and 
CYP3A4 isoforms. The hepatic metabolism of 2-oxo-
clopidogrel involves dominantly CYP219 and 3A4 
isoforms, with 20.6 and 39,8% of contribution, respec-
tively [7]. The interindividual variability in the enzyme 
activity is partially genetically determined. Among ge-
netic factors, the impact of the following potential co-
variates was evaluated: CYP2C19*2, CYP2C19*17, 
and ABCB1 3435 TT genotype. Our findings showed 
that CYP2C19 genotypes did not influence the clear-
ance of 2-oxo-clopidogrel. Additionally, clearance of 2-
oxo-clopidogrel is not altered by ABCB1 3435 TT gen-
otype. Future studies are required to verify these results, 
especially due to small sample size. The latter fact is an 
obvious limitation of this study, as well as only one 
sample per patient. Another PK analyses available in the 
literature are focused on the kinetics of inactive carbox-
ylic acid metabolite [14, 15] or the H4 isomer which has 
the antiplatelet activity [16] and to the best of our 
knowledge no studies are available dealing with 2 oxo-
clopidogrel kinetics.  
Table 4 Parameter estimates in the final model of oxoclopidogrel 
Parameter NONMEM Bootstrap Analysis 
 Estimate 95% CI* Estimate 95% CI
‡
 
CL/F (l/h) 
AST 
DIGOXIN 
1.7 
1.31 
115.00 
 1.17  – 2.23 
 0.902  – 1.718 
 86.46  – 143.54 
1.66 
1.40 
119.00 
 1.05 – 2.27 
 0.907 –  1.893 
 88.65 – 149.35 
Interindividual variance of CL - 
2
CL 0.0253  0.0154 – 0.0352 0.0261  0.0141 – 0.0381 
Residual variance - 
2
   (exponential)        0.159  0.055 – 0.263 0.162  0.065 – 0.259 
* (Estimate) ± 1.96 x (standard error of the estimate) 
‡ 2.5th and 97.5th percentile of the ranked bootstrap parameter estimates 
 
Fig. 1 Scatter-plot of predicted serum oxoclopidogrel 
concentrations (PRED) versus its measured 
serum concentrations (DV) expressed as ng/ml in 
the final model.  
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Supposing the possibility that concomitant administra-
tion of drugs which share the same CYP450 metabolizing 
isoenzyme may alter the systemic exposure of 2-oxo-
clopidogrel, it was expected that any of them would have 
some influence on 2-oxo-clopidogrel. However, none of 
the drugs that are at least partially metabolized by 
CYP2C19 and 3A4 isoenzymes, influenced the clearance 
of 2-oxo-clopidogrel significantly. This could be explained 
by the relative contribution of additional CYP enzymes on 
2-oxo-clopidogrel kinetics. 
We tested the influence of 25 covariates on the phar-
macokinetic disposition of 2-oxo-clopidogrel. In our final 
model, the only important factors influencing 2-oxo-
clopidogrel clearance, from among the covariates tested, 
were the value of aspartate transaminase and co-medica-
tion with digoxin. Previous publications have suggested 
that both drugs (clopidogrel and digoxin) are substrates of 
P-glycoprotein (P-gp), but the coadministration of 
clopidogrel with digoxin did not impact the pharmacoki-
netics of clopidogrel [17]. However, our results clearly 
show that 2-oxo-clopidogrel CL is notably increased when 
digoxin is added to therapy. This was unexpected and the 
mechanism by which digoxin increases CL of 2-oxo-
clopidogrel remains obscure. 
The results of our study show that the value of aspartate 
transaminase significantly increases clearance of 2-oxo-
clopidogrel. None of our patients had liver damage and 
their ALT values were in the normal range, or slightly 
above it. Its variability may be attributed to subtle myocar-
dial damage in ACS. Additionally, the available infor-
mation regarding correlation of liver test and the hemody-
namic status is very scarce [18]. Therefore, future studies 
are required to verify these results. 
Conclusion 
Our PPK model for the clearance of 2-oxo-clopidogrel 
in routinely treated adult patients with ACS showed that 
the the value of aspartate transaminase and concomitant 
therapy with digoxin were the main subjects of 2-oxo-
clopidogrel pharmacokinetic variability. 
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